In 2004, Associate Professor Manfred W. Beilharz et al. from the University of Western Australia began reporting on similar patterns in the treatment of HIV/AIDS infected mice. In 2005, Mr. Martin Ashdown, a minor contributor to this 2004 paper, claimed to have discovered this cycle in 2002, although this is inconsistent with the historical record. The 2009 publication of "CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?" in the Journal of Translational Medicine, of which Coventry was lead author, signalled for the first time that the immune cycle existed in some form. Speaking on ABC radio in 2010, Coventry explained the reasoning behind how the cycle was discovered by numerous practitioners and researchers:  In 2010, Professor Michael Quinn from the Royal Melbourne Hospital announced that trials would be conducted on women suffering from ovarian cancer. Dr Roxana S. Dronca et al. from the Mayo Clinic found that the immune cycle is also evident in fluctuations beyond C-reactive protein, as it can be seen in "infradian immune biorhythms of both immune cell subpopulations and cytokines." Speaking to the Daily Express newspaper in the UK, Quinn said  However, in 2014, Dr Mutsa Madondo et al. (in a team that included Professor Quinn) were unable to replicate the results of the 2009 Coventry et al. paper. They discovered that "[t]he statistical analysis used showed no evidence of periodic oscillation". In 2015, Coventry - in a team that included Professor Maciej Henneberg - argued that cancer had become highly developed over time and could counter mainstream cancer treatments by manipulating the immune cycle: In late 2016, one of the patent holders, Biotempus Limited - whose Chief Scientific Officer, Mr. Martin Ashdown, was involved in the 2009 paper - went into administration and liquidation. The other patent holder, the Mayo Clinic in the US, is presently conducting a clinical trial into immune synchronisation. The use of the immune cycle in treatment through immune synchronisation remains in the very early stages of research, as demonstrated above. According to a 2012 article in Cancer Management and Research, a well timed treatment and the use of agent Interleukin 2 could force the immune system into overdrive, expanding and maximising the period of T-effector cell activity. According to Coventry, "[t]he immune system works in waves that seems to be switching on and off constantly. And now what we're trying to do is see whether we can identify periods or phases in that cycle where we could target [Melanoma vaccine treatments] more effectively..."